Elesclomol (ES) induces ferroptosis in colorectal cancer (CRC) by degrading ATP7A; ES induces copper chelation, then increases copper levels while reducing ATP7A expression, which leads to reactive oxygen species (ROS) accumulation and promotes the degradation of SLC7A11. This evidence concerns the gene ATP7A and colorectal cancer.